Skip to Main Content

Paper Details

Telomerase reverse transcriptase promoter mutation- and O<sup>6</sup>-methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link?
Eur J Cancer
10
2021
C228T, C250T, GGN, Glioma, IDH, IDH-wild-type glioblastoma, MGMT, MGMT promoter, MGMT promoter-methylated glioblastoma, MGMT promoter-methylated tumours, MGMT) promoter-, O6-methylguanine, O6-methylguanine DNA methyltransferase, O6-methylguanine DNA methyltransferase promoter, TERT, TERT promoter, TERT promoter hotspot, TERT promoter mutations, TMZ, Telomerase reverse transcriptase, glioblastoma, isocitrate, isocitrate dehydrogenase, isocitrate dehydrogenase (, isocitrate dehydrogenase-wild-type glioblastoma, patients, telomerase reverse transcriptase, telomerase reverse transcriptase (TERT) promoter, temozolomide
Author NameAffiliation
Marietta WolterInstitute of Neuropathology, Heinrich Heine University
Marcos TatagibaUniversity of Tubingen
Elisabeth J RushingUniversity Hospital and University of Zurich
Torsten PietschUniversity Hospital Bonn
Andreas von DeimlingUniversity Hospital Heidelberg, German Cancer Center (DKFZ)
Michael WellerUniversity Hospital and University of Zurich
Guido ReifenbergerInstitute of Neuropathology, Heinrich Heine University, German Cancer Research Center (DKFZ)
  • 1 - 7

Datasets

Release 1.2